Alexion ($23 billion, -3% YTD) is a pharma company best known for Soliris, a drug used to treat atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria  two rare disorders. Alexion ($23 billion, -3% YTD) is a pharma company best known for Soliris, a drug used to treat atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria  two rare disorders. Alkermes ($3 billion, -4% YTD) is a biopharmaceutical company that focuses on drugs for diseases in the central nervous system including schizophrenia, depression, and multiple sclerosis. Alkermes ($3 billion, -4% YTD) is a biopharmaceutical company that focuses on drugs for diseases in the central nervous system including schizophrenia, depression, and multiple sclerosis. The stocks we picked back then include Novocure (NASDAQ: NVCR), ACADIA (NASDAQ: ACAD), Alexion (NASDAQ: ALXN), and Alkermes (NASDAQ: ALKS).
The company has won awards for best organizations.
( z0 win :ARG0 ( z1 company ) :ARG1 ( z2 award :ARG2 z1 :ARG3 ( z3 organization :ARG1-of ( z4 have-degree :ARG2 ( z5 good :ARG1 z3 ) :ARG3 ( z6 most ) ) ) ) )
(z0 / win-01
    :ARG0 (z1 / company)
    :ARG1 (z2 / award-01
              :ARG2 z1
              :ARG3 (z3 / organization
                        :ARG1-of (z4 / have-degree-91
                                     :ARG2 (z5 / good-02
                                               :ARG1 z3)
                                     :ARG3 (z6 / most)))))
The company has won awards for best organizations .
z0 :ARG0 z1
z0 :ARG1 z2
z2 :ARG2 z1
z4 :ARG2 z5
z4 :ARG3 z6
z5 :ARG1 z3
z3 :ARG1-of z4
z2 :ARG3 z3